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Abstract
Background: Since 2003 pediatric antiretroviral treatment (ART) programs have scaled-up in sub-Saharan Africa
and should be evaluated to assess progress and identify areas for improvement. We evaluated secular trends in the
characteristics and treatment outcomes of children in three pediatric ART clinics in urban and rural areas in
Zambia.
Methods: Routinely collected data were analyzed from three ART programs in rural (Macha and Mukinge) and
urban (Lusaka) Zambia between program implementation and July 2008. Data were obtained from electronic
medical record systems and medical record abstraction, and were categorized by year of program implementation.
Characteristics of all HIV-infected and exposed children enrolled in the programs and all children initiating
treatment were compared by year of implementation.
Results: Age decreased and immunologic characteristics improved in all groups over time in both urban and rural
clinics, with greater improvement observed in the rural clinics. Among children both eligible and ineligible for ART
at clinic enrollment, the majority started treatment within a year. A high proportion of children, particularly those
ineligible for ART at clinic enrollment, were lost to follow-up prior to initiating ART. Among children initiating ART,
clinical and immunologic outcomes after six months of treatment improved in both urban and rural clinics. In the
urban clinics, mortality after six months of treatment declined with program duration, and in the rural clinics, the
proportion of children defaulting by six months increased with program duration.
Conclusions: Treatment programs are showing signs of progress in the care of HIV-infected children, particularly in
the rural clinics where scale-up increased rapidly over the first three years of program implementation. However,
continued efforts to optimize care are needed as many children continue to enroll in ART programs at a late stage
of disease and thus are not receiving the full benefits of treatment.
Background
At the end of 2008, approximately 3 million people were
receiving antiretroviral therapy (ART) in sub-Saharan
Africa, including over 200,000 children, representing a
substantial increase in coverage for those in need since
the World Health Organization (WHO) announced its
‘3b y5 ’ initiative in 2003 [1,2]. Recent studies have
demonstrated that children receiving ART in sub-
Saharan Africa can achieve comparable outcomes to
children in high-income countries [3]. However, higher
mortality rates have been observed due to treatment
initiation at more advanced stages of disease [4]. As
treatment programs scale-up and more HIV-infected
women receive prevention of mother-to-child transmis-
sion (PMTCT) services, awareness of the availability of
testing and treatment services for infants and children
should increase. This increased awareness should be
accompanied by improvements in the profile of children
enrolling in ART programs, as infants and children are
brought for testing and treatment earlier, prior to the
development of signs and symptoms of advanced
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Saharan Africa, baseline CD4
+ T-cell counts increased
with increasing duration of program implementation
[5-7], and mortality rates post-ART initiation decreased
[7]. However, several studies found increases in loss-to-
follow-up as programs expanded and are burdened with
tracking growing patient populations [7,8].
Evaluation of pediatric ART programs over time can
be an effective method to assess the progress of these
programs, not only by characterizing the age, stage of
disease and outcomes of HIV-infected children accessing
treatment services, but also by ascertaining the number
of HIV-exposed children enrolled, which provides a
measure of how well pediatric and maternal health pro-
grams within healthcare facilities are collaborating to
identify HIV-exposed infants.
Monitoring and evaluating pediatric ART programs in
different settings, including rural and urban areas, will
also be important, as rural clinics may face different
challenges at the level of the provider and caregiver,
including shortages of healthcare workers, drugs or
laboratory equipment and greater travel distances to the
clinic [9,10]. These factors could affect the characteris-
tics of the patient population as well as treatment out-
comes over time. We evaluated secular trends in the
characteristics and treatment outcomes of children in
three pediatric ART clinics in urban and rural areas of
Zambia between 2004 and 2008.
Methods
Study Population
The study was conducted in two rural and one urban
pediatric HIV clinic in Zambia. The urban clinic,
Matero Reference Clinic, is located in a low-income
community in Lusaka and is one of 18 Ministry of
Health facilities supported by the Centre for Infectious
Disease Research in Zambia ( C I D R Z )t h a th a sp r o v i d e d
treatment to HIV-infected children since May 2004.
Matero Reference Clinic has a similar pediatric patient
population with comparable treatment outcomes to the
other CIDRZ clinics in Lusaka [11].
The two rural clinics were Macha Mission Hospital
and Mukinge Hospital. Macha Mission Hospital, located
in Southern Province, is a district-level hospital adminis-
tered by the Brethren in Christ Church serving a popu-
lation of over 150,000 people [12,13]. Mukinge Hospital,
located in Mukinge in North Western Province, is a dis-
trict-level hospital administered by the Evangelical
Church in Zambia serving a population of over 100,000
people. The HIV clinics in Macha and Mukinge func-
tion within the healthcare system of the Ministry of
Health and began administering ART in March 2005.
As faith-based health facilities, Macha and Mukinge may
have different support and healthcare personnel than
rural government clinics. Both rural areas have lower
population densities than Lusaka (63.5 per km
2 in
Lusaka, 14.2 per km
2 in Southern Province and 4.6 per
km
2 in North Western Province), and are populated pri-
marily by subsistence farmers [14].
The study was approved by the University of Zambia
Research Ethics Committee, the Ministry of Health of
Zambia, and the Institutional Review Board at the Johns
Hopkins Bloomberg School of Public Health.
Clinic Procedures
Clinic procedures were similar at all three clinics. Chil-
dren with a positive serological test for HIV were eligi-
ble for enrollment. At the initial evaluation visit,
children underwent a medical history, physical examina-
tion, anthropometric measurements, collection of socio-
demographic information, and determination of WHO
disease stage. Standard of care included measurement of
CD4
+ T-cell counts and percentages (not available in
Macha/Mukinge in the first year of the program), hemo-
globin levels, and renal and liver function tests. Capacity
to routinely measure HIV viral loads was not available.
Staffing in the three clinics was similar, with 1-2 physi-
cians, 1-2 clinical officers and several nurses and coun-
selors in the clinic at any time.
Treatment eligibility was determined based on WHO
[15,16] treatment guidelines in effect at the time. For
HIV-seropositive infants younger than 18 months,
DNA-based diagnostic testing methods were available in
Lusaka in 2007. However, they were not widely used by
public-sector health clinics until 2008 and only became
available in Macha and Mukinge in February 2008. Con-
sequently, infection in these children could not be
laboratory-confirmed during the study period. HIV-sero-
positive infants diagnosed with severe disease or immu-
nodeficiency were presumptively treated, as
recommended by WHO treatment guidelines [16].
Children determined to be eligible were treated with a
first-line regimen consisting of two nucleoside reverse
transcriptase inhibitors (stavudine or zidovudine or aba-
cavir plus lamivudine) and one non-nucleoside reverse
transcriptase inhibitor (efavirenz or nevirapine), and
asked to return for clinical evaluation every three
months. Laboratory measurements were performed
every six months or when clinically indicated. Children
not receiving ART returned for clinical and laboratory
evaluation every three months. Attempts were made to
trace children who missed scheduled appointments to
ascertain whether they had died, moved or dropped out
of the program (defaulted).
Statistical Methods
Data were collected between program implementation
and July 31, 2008 from the CAREWare electronic
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from medical record abstraction at Matero Reference
Clinic (95% of pediatric files were located). The duration
of program implementation was divided into four years
for Matero (Year 1: Aug 2004-July 2005; Year 2: Aug
2005-July 2006; Year 3: Aug 2006-Aug 2007; Year 4:
Aug 2007-July 2008) and three years for Macha and
Mukinge (Year 1: Mar 2005-Feb 2006; Year 2: Mar
2006-Feb 2007; Year 3: Mar 2007-Feb 2008) (Figure 1).
For analyses at the initial evaluation visit, all HIV-sero-
positive treatment-naïve children younger than 15 years
a n de n r o l l e di nt h eH I Vp r o grams during the specified
years of program implementation were included. When
comparing HIV-related characteristics at the initial eva-
luation visit, the analysis was restricted to children with
confirmed (≥18 months old) or presumed (<18 months
old) infection. Children younger than 18 months at
enrollment who were presumptively diagnosed and trea-
ted or who were older than 18 months of age with a
positive serological test by July 2008 were presumed to
be HIV-infected at enrollment. Severe immunodefi-
ciency was defined by age-specific CD4
+ T-cell percen-
tages or CD4
+ T-cell counts according to the 2006
WHO guidelines [16]. Eligibility for ART at clinic
enrollment was defined retrospectively based on the
treatment guidelines in effect at the time the child
enrolled in the clinic (the 2003 guidelines were assumed
to have been in effect until June 1, 2006). As the 2003
guidelines relied more heavily on clinical judgment for
certain groups, eligibility was defined as initiating ART
within 90 days of enrollment for children with ambigu-
ous or missing WHO stage and CD4
+ T-cell percentage.
Laboratory measures within 90 days were used if none
were available from the initial evaluation visit.
Outcomes for HIV-infected children were determined
one year after enrollment and were evaluated by eligibil-
ity for ART at the initial evaluation visit. Outcomes
included initiating ART and remaining in care, and
transferring to another clinic, dying or defaulting with-
out initiating ART. Children who missed at least two
clinic visits scheduled three months apart by the end of
follow-up (i.e., had not been seen in the clinic since Jan-
uary 1, 2008) were assumed to have defaulted and were
censored at their last visit. As outcomes were defined
after one year in the clinic, the last year of program
implementation was excluded from this analysis.
For time trends after ART initiation, the analysis was
restricted to all children younger than 15 years with
Figure 1 Enrollment over time in three pediatric HIV programs in urban and rural Zambia. Monthly enrollment of HIV-exposed and
infected children in two rural and one urban HIV clinic in Zambia between August 2004 and July 2008.
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ART during the specified years of program implementa-
tion. Characteristics at ART initiation were evaluated,
including laboratory measures within 90 days prior to
ART initiation. The child’s status was determined after
six months on ART. Clinical and immunologic out-
comes were assessed at six months post-ART initiation.
Immunologic outcomes were assessed by determining
the median CD4
+ T-cell percentage (both absolute and
change from ART initiation) at the six month visit. Clin-
ical outcomes were assessed by determining the propor-
tion of children who were underweight at the six month
visit. Weight-for-age z-scores (WAZ) were used to
determine nutritional status and were calculated using
the WHO growth standards as a reference and statistical
software provided by WHO [17]. Children with WAZ
scores below -2 were considered to be underweight. For
this analysis, the CD4
+ T-cell percentage and WAZ clo-
sest to six months after initiation of ART (+/- 2
months) was used.
Mantel-Haenszel c
2 and Cuzick’s non-parametric test
were used to test for trends in categorical and continu-
ous variables, respectively. Analyses were conducted
using SAS for Windows, version 9.1 (SAS Institute Inc,
Cary, North Carolina) and STATA, version 9 (StataCorp
LP, College Station, Texas).
Results
Changes in the characteristics of children at the initial
evaluation over time
All children enrolled in the clinics
During the study period, 588 and 690 children were
enrolled in the urban and rural (606 in Macha and 84 in
Mukinge) clinics, respectively (Figure 1). In the urban
clinic, the number of children enrolled decreased over
time. There was a non-significant trend towards
decreasing age at enrollment over time (Table 1); how-
ever, the median age remained high in the fourth year
of implementation. No differences in enrollment by gen-
der or township of residence were observed over time.
In the rural clinics, enrollment increased over time
(Table 2), largely due to an increase in the number of
HIV-exposed children in Macha, which lead to a signifi-
cant decrease in the age at enrollment. No differences in
enrollment by gender were observed over time. The
median distance travelled to the clinic also significantly
increased over time.
HIV-infected children
Similar non-significant decreases in age at enrollment
were observed among HIV-infected children in the
urban clinic (Table 1). In addition, the proportion of
children with a history of tuberculosis significantly
decreased over time. In contrast, the proportion of chil-
dren with severe immunodeficiency remained stable and
the proportion of children presenting with WHO stage
3 or 4 disease increased significantly over time, resulting
in a significant increase in the proportion of children
who were eligible for ART at the initial evaluation visit.
Among HIV-infected children in the rural clinics, the
median age was lower than that of urban children and
decreased significantly over time (Table 2). The chil-
dren’s clinical status also significantly improved over
time, with the proportion reporting a history of tubercu-
losis and WHO stage 3 or 4 decreasing over time.
The availability of laboratory tests increased over time
in the rural clinics, with few children undergoing tests
to measure immune status in the first year of the pro-
gram. In the second and third years of program imple-
mentation, when at least half of the children had
measures available, the proportion with severe immuno-
deficiency decreased, resulting in a decrease in the pro-
portion of children eligible for ART at initial evaluation.
Changes in outcomes among HIV-infected children
eligible and ineligible for ART at clinic enrollment
In both urban and rural clinics, no significant changes
over time in outcomes were observed for children who
were eligible and ineligible for ART at enrollment
(Table 3). The majority of children who were eligible
initiated ART within a year but reasons for remaining in
care without initiating ART were not available. Among
eligible children who did not remain in care, a small
proportion died or transferred to other clinics but the
majority (approximately 10% of all eligible children)
were lost to follow-up.
Among children ineligible for ART at enrollment, up
to 50% initiated ART within one year and approximately
30% remained alive and in care. Of those children who
did not remain in care, the majority (up to 30% of all
ineligible children) were lost to follow-up.
Changes in outcomes among HIV-infected children
receiving ART
During the study period, 436 and 171 children started
ART in the urban and rural clinics, respectively (Figure
2 ) .A tA R Ti n i t i a t i o n ,c h a n g e so v e rt i m ei na g ea n d
CD4
+ T-cell percentage in both urban and rural clinics
were similar to those observed at enrollment, with
decreases in age and increases in CD4
+ T-cell percen-
tage at ART initiation (Table 4). Among children on
ART in the urban clinic, there were no significant differ-
ences over time in the proportion of children who trans-
ferred to other ART programs or who defaulted after six
months on ART (Table 3). There was a significant
decrease in the proportion of deaths within six months
of initiating ART, resulting in an increase in the propor-
tion of children remaining in care over time. Immunolo-
gic outcomes improved, although trends were not
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the proportion of underweight children, initially wor-
sened and then improved in the fourth year of the
program.
Among children in the rural clinics, there were no sig-
nificant differences over time in the proportion of chil-
dren who died or transferred to another ART program
after six months of ART (Table 4). However, the pro-
portion of children who defaulted increased significantly
over time, resulting in a decrease in the proportion of
children remaining in care. Both immunologic and clini-
cal outcomes after six months of ART improved over
time, although these trends were not statistically
significant.
Discussion
In this study of trends in the characteristics of children
enrolling in ART programs and initiating ART in urban
and rural Zambia, signs of progress were evident in the
first years of program implementation but differed
between rural and urban clinics, reflecting differences
not only in the characteristics of the population attend-
ing the clinics but also in program implementation,
infrastructure and integration. In evaluating characteris-
tics of HIV-infected children enrolling in ART pro-
grams, we were able to examine the success of these
programs in improving the availability of ART and pro-
moting testing of children at younger ages and earlier
stages of disease progression. The older age and later
stage of disease of HIV-infected children observed in
this study, in particular in the urban clinic, are consis-
tent with other studies of HIV-infected children in sub-
Saharan Africa [3,18], and resulted in the majority of
children being eligible for ART at the time of enroll-
ment. Concerns have been raised that treatment is
initiated late in disease progression, reducing its
Table 1 Characteristics at initial evaluation at an HIV clinic in Lusaka, Zambia, by year of enrollment
First Year
N (%)
Second Year
N (%)
Third Year
N (%)
Fourth Year
N (%)
p-trend
a
All children n = 206 n = 146 n = 114 n = 122
Age (yrs): Median (IQR) 6.9 (3.4, 10.0) 5.9 (2.5, 9.4) 5.6 (2.5, 9.1) 5.5 (1.8, 10.3) 0.12
< 1 12 (5.8) 4 (2.7) 5 (4.4) 13 (10.7) 0.14
1-1.9 25 (12.1) 23 (15.8) 17 (14.9) 20 (16.4)
2-4.9 45 (21.8) 34 (23.3) 30 (26.3) 21 (17.2)
5-9.9 70 (34.0) 57 (39.0) 38 (33.3) 37 (30.3)
≥ 10 54 (26.2) 28 (19.2) 24 (21.1) 31 (25.4)
Male sex 111 (54.2) 74 (50.7) 56 (49.6) 64 (52.9) 0.71
Resides in Matero Township 66 (32.2) 51 (35.2) 38 (33.3) 40 (33.1) 0.90
HIV-infected children n = 199 n = 140 n = 109 n = 114
Age (yrs): Median (IQR) 7.1 (3.6, 10.2) 6.4 (2.9, 9.6) 6.0 (3.1, 9.5) 6.1 (2.2, 10.5) 0.24
Male sex 107 (54.0) 72 (51.4) 55 (50.9) 61 (53.5) 0.84
Self-reported history of tuberculosis 81 (42.4) 37 (26.6) 32 (30.8) 22 (20.8) 0.0003
Missing 8 (4.0) 1 (0.7) 5 (4.6) 8 (7.0)
WAZ: Median (IQR) -2.0 (-3.1, -1.0) -2.5 (-3.8, -1.8) -1.9 (-3.1, -1.0) -2.7 (-4.1, -1.5)
Underweight 70 (49.7) 75 (70.1) 38 (48.1) 44 (62.0) 0.34
Missing 58 (29.1) 33 (23.6) 30 (27.5) 43 (37.7)
WHO stage
1 34 (17.3) 7 (5.0) 10 (9.2) 14 (12.3) <0.0001
2 82 (41.6) 23 (16.6) 22 (20.2) 19 (16.7)
3 or 4 81 (41.1) 109 (78.4) 77 (70.6) 81 (71.1)
Missing 2 (1.0) 1 (0.7) 0 (0.0) 0 (0.0)
CD4%: Median (IQR) 11.9 (5.8, 17.5) 13.3 (6.9, 19.4) 13.2 (8.3, 18.8) 15.1 (9.1, 21.9) 0.001
Missing 24 (12.1) 13 (9.3) 4 (3.7) 4 (3.5)
Severe immunodeficiency
b 120 (66.3) 75 (59.1) 66 (62.9) 64 (58.2) 0.22
CD4 count (cells/mm
3): Median (IQR) 356 (132, 603) 328 (135, 531) 439 (214, 611) 429 (209, 766) 0.004
Missing 19 (9.5) 13 (9.3) 4 (3.7) 4 (3.7)
Eligible for ART
c 146 (73.4) 122 (87.1) 92 (84.4) 95 (83.3) 0.02
IQR: interquartile range; WAZ: Weight-for-age z-score (only for children younger than 10 years); WHO: World Health Organization; ART: antiretroviral therapy.
a p-trend calculated from Mantel-Haenszel c
2 for categorical variables and Cuzick’s non-parametric test for trend for continuous variables.
b severe immunodeficiency defined by age according to the 2006 World Health Organization guidelines.
c determined retrospectively based on the WHO guidelines in effect at the time of the initial evaluation
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dren earlier should result in treatment before signs and
symptoms of severe disease.
In comparison to the urban clinics, and contrary to
studies among adults initiating ART in urban and rural
areas [20,21], children in the rural clinics appeared to
enroll in care and initiate ART at younger ages and ear-
lier stages of disease, and to have greater improvements
in these measures over time. It is encouraging that
despite the many obstacles to care in rural areas, these
rural clinics have been able to address these issues and
make improvements, which may translate into better
treatment outcomes [3,11].
We not only examined trends among HIV-infected
children but also among all children, both HIV-exposed
and HIV-infected, enrolled in the clinics. As treatment
and PMTCT programs scale-up and awareness increases
about HIV/AIDS and testing and treatment services,
ART clinics will see an increase in the number of
enrolled HIV-exposed children. This pattern was
observed in the rural clinics, where the number of chil-
dren enrolled increased more than five times in the first
t h r e ey e a r s ,l a r g e l yd u et oa ni n c r e a s ei nt h en u m b e ro f
HIV-exposed children. Increased awareness in the com-
munity is supported by the observed increase in the dis-
tances travelled to the clinic over time.
Table 2 Characteristics of HIV-exposed and infected children at initial evaluation in two rural clinics in Zambia by year
of enrollment
First Year
N (%)
Second Year
N (%)
Third Year
N (%)
p-trend
a
All children N = 66 n = 159 n = 352
Age (yrs): Median (IQR) 3.1 (1.0, 8.1) 1.7 (0.6, 5.2) 0.4 (0.0, 1.9) <0.0001
<1 17 (25.8) 57 (35.9) 224 (63.6) <0.0001
1-1.9 9 (13.6) 31 (19.5) 46 (13.1)
2-4.9 17 (25.8) 26 (16.4) 38 (10.8)
5-9.9 14 (21.2) 29 (18.2) 31 (8.8)
≥ 10 9 (13.6) 16 (10.1) 13 (3.7)
Male sex 34 (51.5) 68 (42.8) 182 (51.7) 0.38
Distance travelled (km): 0.008
Median (IQR) 22 (9, 40) 30 (13, 48) 35 (20, 50)
Missing 11 (16.7) 41 (25.8) 80 (22.7)
HIV-infected children N = 48 N = 99 n = 124
Age (yrs): Median (IQR) 4.9 (2.6, 9.3) 3.9 (1.9, 7.5) 2.8 (1.7, 6.5) 0.003
Male sex 24 (50.0) 41 (41.4) 66 (53.2) 0.39
Self-reported history of tuberculosis 13 (27.1) 11 (11.1) 15 (12.1) 0.04
WAZ: Median (IQR) -3.0 (-3.8, -2.3) -2.3 (-4.1, -1.5) -3.0 (-3.9, -1.5)
Underweight 27 (81.8) 43 (57.3) 69 (70.4) 0.71
Missing 15 (31.3) 24 (24.2) 26 (21.0)
WHO stage
1 4 (10.8) 9 (11.5) 16 (18.8) 0.04
2 10 (27.0) 32 (41.0) 34 (40.0)
3 or 4 23 (62.2) 37 (47.4) 35 (41.2)
Missing 11 (22.9) 21 (21.2) 39 (31.5)
CD4%: Median (IQR) 19.0 (9.0, 25.0) 13.0 (9.5, 19.4) 20.2 (13.7, 27.6) 0.01
Missing 41 (85.4) 50 (50.5) 45 (36.3)
Severe immunodeficiency
b 3 (25.0) 36 (60.0) 36 (41.9) 0.59
CD4 count (cells/mm
3):
Median (IQR) 453 (257, 663) 513 (264, 786) 693 (338, 998) 0.01
Missing 36 (75%) 39 (39.4) 38 (30.6)
Eligible for ART
c 22 (55.0) 58 (61.7) 61 (54.5) 0.69
Missing 8 (16.7) 5 (5.1) 12 (9.7)
IQR: interquartile range; WAZ: Weight-for-age z-score (only for children younger than 10 years); WHO: World Health Organization; ART: antiretroviral therapy.
a p-trend calculated from Mantel-Haenszel c
2 for categorical variables and Cuzick’s non-parametric test for trend for continuous variables.
b severe immunodeficiency defined by age according to the 2006 WHO guidelines.
c determined retrospectively based on the WHO guidelines in effect at the time of the initial evaluation
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where enrollment decreased over time and few infants
were enrolled. These differences in age distribution can
be attributed to differing procedures, with the rural
clinics having more active enrollment procedures than
the urban clinic. In the rural clinics, HIV-exposed chil-
dren were tested and referred to the ART clinic from
maternal and child health and pediatric programs and
were followed until their HIV status could be confirmed.
In the urban clinic, there was less collaboration between
programs and higher attrition among referrals [22], such
that many infants were either not tested or contact was
lost before they obtained their test results and could be
referred to the ART clinic. Under this system, the onus
was on the caregiver to seek testing, care and treatment
for their child.
These findings have implications for treatment pro-
grams in light of recent revisions to the treatment
guidelines, recommending treatment of HIV-infected
children younger than 2 years [23] following the results
of the Children with HIV Early Antiretroviral Therapy
(CHER) trial in South Africa [24]. Implementation of
these recommendations requires that HIV-exposed chil-
dren be identified and infection confirmed in order to
initiate treatment, a process that appears to be working
well in the rural clinics where a large group of HIV-
exposed children are enrolled and can benefit from the
new treatment guidelines. Similar progress has not been
achieved in the urban clinic where continued work is
needed to promote HIV testing and collaboration, and
integration of pediatric, nutrition, and maternal health
programs within healthcare facilities. As more infants
are enrolled into these programs, further research will
be needed on how well these children respond to treat-
ment, as much of the data on clinical, immunologic, and
virologic outcomes from sub-Saharan Africa come from
studies of older children.
Outcomes among eligible and ineligible children did
not vary over time but demonstrated that these pro-
grams were successfully starting children on treatment,
as the majority of eligible and ineligible children in both
urban and rural clinics initiated ART within a year of
clinic enrollment. Fewer eligible children appeared to
initiate ART in the rural clinics, possibly due to the
high levels of malnutrition in these areas. Severe malnu-
trition is an indicator for severe disease (WHO stage 3)
but by itself would not indicate eligibility for ART. A
major concern was the high proportion of children lost
to follow-up prior to initiating ART, particularly among
children who were ineligible for ART. This represents
substantially higher losses than those reported for chil-
dren receiving ART [18]. The reasons for loss to follow-
up are not completely understood, although a propor-
tion due to unreported transfers and deaths are
expected [25-27]. Resources should be directed towards
retention to ensure that all children remain in care and
are appropriately monitored.
Consistent with our findings at clinic enrollment, the
profile of children initiating ART in urban and rural
clinics improved with increasing program duration. This
also has been observed in studies among adults in sub-
Saharan Africa [5-7]. Outcomes were assessed after six
months of treatment and mortality and loss to follow-up
were within the ranges reported from other pediatric
ART programs in sub-Saharan Africa [3,18]. Mortality
appeared to be higher in the rural clinics and remained
constant over time despite initiation at earlier stages of
disease, perhaps due to increases in enrollment of
younger children who are more likely to have high mor-
tality [3,11]. In contrast, mortality in the urban clinic
declined, a pattern which has been observed among
adults initiating treatment in South Africa, and was
attributed to improvements in the clinical profile of
Table 3 One year retention and outcomes by ART
eligibility status at initial evaluation among HIV-infected
children in urban and rural Zambia
First year
N (%)
Second year
N (%)
Third year
N (%)
p-
trend
a
Urban
Eligible for ART
b N = 146 N = 122 N = 92 0.39
On ART 131 (89.7) 99 (81.2) 78 (84.8)
Alive, not on ART 3 (2.1) 3 (2.5) 3 (3.3)
Died 1 (0.7) 3 (2.5) 1 (1.1)
Defaulted 11 (7.5) 17 (13.9) 9 (9.8)
Transferred 0 (0.0) 0 (0.0) 1 (1.1)
Ineligible for ART
b N = 53 N = 18 N = 17 0.87
On ART 20 (37.7) 9 (50.0) 4 (23.5)
Alive, not on ART 17 (32.1) 5 (27.8) 6 (32.3)
Died 0 (0.0) 1 (5.6) 1 (5.9)
Defaulted 14 (26.4) 3 (16.7) 5 (29.4)
Transferred 2 (3.8) 0 (0.0) 1 (5.9)
Rural
Eligible for ART
b N = 22 N = 58 0.29
On ART 18 (81.8) 33 (56.9)
Alive, not on ART 2 (9.1) 17 (29.3)
Died 0 (0.0) 0 (0.0)
Defaulted 2 (9.1) 8 (13.8)
Transferred 0 (0.0) 0 (0.0)
Ineligible for ART
b N = 18 N = 36 0.63
On ART 9 (50.0) 7 (19.4)
Alive, not on ART 6 (33.3) 16 (44.4)
Died 0 (0.0) 2 (5.6)
Defaulted 3 (16.7) 11 (30.6)
Transferred 0 (0.0) 0 (0.0)
a p-trend calculated from Mantel-Haenszel c
2
b determined retrospectively based on the WHO guidelines in effect at the
time of the initial evaluation
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Page 7 of 10individuals initiating treatment [7]. However, in this
study, greater improvements were observed in the rural
clinics without any decrease in mortality. As predictors
of mortality over time were not evaluated and the com-
pleteness of patient tracing in either location is
unknown, we cannot determi n ew h e t h e rt h eo b s e r v e d
decrease in mortality in the urban clinic was in fact due
to better survival resulting from improved clinical status
at ART initiation or differential ascertainment of deaths
in the clinics.
Loss to follow-up after ART initiation in the urban
clinics remained stable over time. In the rural clinics
losses increased, a pattern that has also been observed
in adult programs [7,8]. This may be due to the large
increase in enrollment over time, thereby reducing the
ability of clinic staff to monitor and manage the patient
load, or to the increasing distances patients travelled to
the clinic, which was found to be associated with higher
loss to follow-up in this population [28].
There were several limitations to this study. As the
study was based on data abstracted from medical
records, all relevant information was not available, and
t h ed a t at h a tw e r ea v a i l a b l ew e r en o tc o m p l e t e ,
particularly for the anthropometric and laboratory mea-
sures. The completeness of the data was not associated
with disease severity but was associated with age;
younger children were more likely to have incomplete
data, perhaps due to the increased difficulties in obtain-
ing blood specimens from infants. The laboratory mea-
sures were performed more consistently in later years of
program implementation, particularly in the rural clinics
as the supply of reagents became more secure. In addi-
tion, these clinics, while typical of HIV clinics and sub-
ject to the same challenges and constraints as other
clinics in this setting, may not be representative of all
pediatric clinics in rural and urban areas of Zambia or
other countries in this region.
Conclusions
Progress has been made in the care of HIV-infected
children in both urban and rural clinics. However, con-
tinued efforts are needed as many children continue to
enter care at a late stage of disease and thus are not
receiving the full benefits of treatment. As programs
continue to expand, emphasis needs to shift to earlier
identification of HIV-infected and exposed children,
Figure 2 Number of children initiating ART over time in three pediatric HIV programs in urban and rural Zambia. Monthly and
cumulative number of HIV-infected children initiating ART in two rural and one urban HIV clinic in Zambia between August 2004 and July 2008.
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Page 8 of 10through promotion of counseling and testing, coordina-
tion between maternal and child health programs, and
retention of children in care.
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Table 4 Retention and outcomes for HIV-infected children in the first 6 months of antiretroviral therapy in Zambia, by
year of enrollment
First Year
N (%)
Second Year
N (%)
Third Year
N (%)
Fourth Year
N (%)
p-trend
a
Urban n = 119 n = 133 n = 87 N = 97
At ART initiation
Age (yrs): Med (IQR) 7.4 (3.6, 10.6) 6.8 (3.0, 9.7) 7.0 (3.7, 9.9) 6.0 (2.4, 9.1) 0.21
CD4%: Med (IQR) 8.8 (4.8, 12.7) 11.6 (6.8, 17.5) 11.4 (7.1, 16.0) 12.8 (9.0, 18.6) <0.0001
Missing 11 (9.2) 17 (12.8) 4 (4.6) 3 (3.1)
At 6 months
Still receiving care 90 (75.6) 104 (78.2) 67 (77.0) 86 (88.7) 0.03
Death 8 (6.7) 12 (9.0) 3 (3.5) 0 (0.0) 0.009
Transferred 7 (5.9) 7 (5.3) 7 (5.1) 4 (4.1) 0.81
Defaulted 14 (11.8) 10 (7.5) 10 (11.5) 7 (7.2) 0.44
Immunologic outcome N = 49 (54.4)
b N = 67 (64.4) N = 47 (70.2) N = 33 (38.4)
CD4%: Med (IQR) 22.7 (15.9, 27.8) 24.5 (19.7, 33.1) 22.7 (16.0, 28.5) 26.7 (22.4, 31.8) 0.15
Change in CD4%: Med (IQR)
c 12.4 (8.1, 15.9) 13.3 (9.1, 17.7) 10.3 (4.2, 14.3) 12.8 (6.7, 16.6) 0.24
Clinical outcome N = 48 (53.3)
b N = 74 (71.2) N = 49 (73.1) N = 35 (40.7)
WAZ < -2 18 (37.5) 32 (43.2) 21 (42.9) 11 (31.4) 0.65
Rural n = 19 n = 39 n = 71
At ART initiation
Age (yrs): Med (IQR) 8.1 (3.4, 10.1) 6.5 (1.9, 10.7) 3.1 (1.7, 7.3) 0.03
CD4%: Med (IQR) 9.0 (9.0, 9.0) 11.8 (8.0, 16.0) 13.7 (9.5, 18.4) 0.23
Missing 18 (94.7) 13 (33.3) 27 (38.0)
At 6 months
Still receiving care 16 (84.2) 31 (79.5) 51 (71.8) 0.21
Death 2 (10.5) 5 (12.8) 9 (12.7) 0.84
Transferred 1 (5.3) 2 (5.1) 3 (4.2) 0.81
Defaulted 0 (0.0) 1 (2.6) 8 (11.3) 0.04
Immunologic outcome N = 4 (25.0)
b N = 13 (41.9) N = 20 (39.2)
CD4%: Med (IQR) 12.1 (10.6, 28.8) 19.4 (14.4, 33.1) 25.9 (18.2, 32.9) 0.22
Change in CD4%: Med (IQR)
c 3.4 (3.4, 3.4) 7.7 (-2.4, 20.0) 12.6 (4.9, 21.0) 0.29
Clinical outcome N = 12 (75.0)
b N = 18 (58.1) N = 32 (62.8)
WAZ < -2 8 (66.7) 10 (55.6) 16 (50.0) 0.33
ART: antiretroviral therapy; WAZ: Weight-for-age z-score (only for children younger than 10 years); IQR: interquartile range
a p-trend calculated from Mantel-Haenszel c
2 for categorical variables and Cuzick’s non-parametric test for trend for continuous variable.
b Numbers in parentheses represent the proportion of those receiving care at 6 months for whom a measure is available
c Samples sizes are smaller than indicated due to missing data at ART initiation
Sutcliffe et al. BMC Pediatrics 2010, 10:54
http://www.biomedcentral.com/1471-2431/10/54
Page 9 of 10References
1. The 3 by 5 Initiative. [http://www.who.int/3by5/en/].
2. WHO: Towards universal access: scaling up priority HIV/AIDS
interventions in the health sector. Progress report 2009. Geneva,
Switzerland: World Health Organization 2009.
3. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ: Effectiveness of
antiretroviral therapy among HIV-infected children in sub-Saharan Africa.
The Lancet infectious diseases 2008, 8:477-489.
4. De Baets AJ, Ramet J, Msellati P, Lepage P: The unique features of
pediatric HIV-1 in sub-Saharan Africa. Current HIV research 2008, 6:351-362.
5. Keiser O, Anastos K, Schechter M, Balestre E, Myer L, Boulle A, Bangsberg D,
Toure H, Braitstein P, Sprinz E, et al: Antiretroviral therapy in resource-
limited settings 1996 to 2006: patient characteristics, treatment
regimens and monitoring in sub-Saharan Africa, Asia and Latin America.
Trop Med Int Health 2008, 13:870-879.
6. Bekker LG, Myer L, Orrell C, Lawn S, Wood R: Rapid scale-up of a
community-based HIV treatment service: programme performance over
3 consecutive years in Guguletu, South Africa. South African medical
journal 2006, 96:315-320.
7. Boulle A, Bock P, Osler M, Cohen K, Channing L, Hilderbrand K, Mothibi E,
Zweigenthal V, Slingers N, Cloete K, et al: Antiretroviral therapy and early
mortality in South Africa. Bulletin of the World Health Organization 2008,
86:678-687.
8. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, Nash D,
Schechter M, Laurent C, Keiser O, May M, et al: Early loss of HIV-infected
patients on potent antiretroviral therapy programmes in lower-income
countries. Bulletin of the World Health Organization 2008, 86:559-567.
9. WHO: Taking Stock: Health worker shortages and the response to AIDS.
Geneva, Switzerland: World Health Organization 2006.
10. WHO: Towards Universal Access: Scaling up Priority HIV/AIDS
Interventions in the Health Sector. Progress Report 2008. Geneva,
Switzerland: World Health Organization 2008.
11. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM,
Chi BH, Sinkala M, Kankasa C, Wilson CM, Wilfert CM, et al: Clinical
outcomes and CD4 cell response in children receiving antiretroviral
therapy at primary health care facilities in Zambia. JAMA 2007,
298:1888-1899.
12. Van Dijk JH, Sutcliffe CG, Munsanje B, Hamangaba F, Thuma PE, Moss WJ:
Barriers to the care of HIV-infected children in rural Zambia: a cross-
sectional study. BMC infectious diseases 2009, 9:169.
13. Carlucci JG, Kamanga A, Sheneberger R, Shepherd BE, Jenkins CA, Spurrier J,
Vermund SH: Predictors of adherence to antiretroviral therapy in rural
Zambia. Journal of acquired immune deficiency syndromes 2008, 47:615-622.
14. Census 2000. [http://www.zamstats.gov.zm/census.php].
15. WHO: Scaling up antiretroviral therapy in resource-limited settings:
treatment guidelines for a public health approach, 2003 revision.
Geneva: WHO 2004.
16. WHO: Antiretroviral therapy of HIV infection in infants and children:
Towards universal access. Recommendations for a public health
approach. Geneva, Switzerland: World Health Organization 2006.
17. The WHO Child Growth Standards. [http://www.who.int/childgrowth/en/].
18. The KIDS-ART-LINC Collaboration: Low risk of death, but substantial
program attrition, in pediatric HIV treatment cohorts in Sub-Saharan
Africa. Journal of acquired immune deficiency syndromes 2008, 49:523-531.
19. Ford N, Mills E, Calmy A: Rationing antiretroviral therapy in Africa–
treating too few, too late. The New England journal of medicine 2009,
360:1808-1810.
20. Rosen S, Ketlhapile M, Sanne I, Desilva MB: Characteristics of Patients
Accessing Care and Treatment for HIV/AIDS at Public and
Nongovernmental Sites in South Africa. J Int Assoc Physicians AIDS Care
2008, 7:200-207.
21. Rosen S, Long L, Sanne I: The outcomes and outpatient costs of different
models of antiretroviral treatment delivery in South Africa. Trop Med Int
Health 2008, 13:1005-1015.
22. Chi BH, Chintu N, Lee A, Stringer EM, Sinkala M, Stringer JS: Expanded
services for the prevention of mother-to-child HIV transmission: field
acceptability of a pilot program in Lusaka, Zambia. Journal of acquired
immune deficiency syndromes 2007, 45:125-127.
23. WHO: Antiretroviral therapy for HIV infection in infants and children:
Towards universal access. Executive summary of recommendations.
Geneva, Switzerland: World Heatlh Organization 2010.
24. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, Jean-
Philippe P, McIntyre JA: Early antiretroviral therapy and mortality among
HIV-infected infants. The New England journal of medicine 2008,
359:2233-2244.
25. Dalal RP, Macphail C, Mqhayi M, Wing J, Feldman C, Chersich MF,
Venter WD: Characteristics and outcomes of adult patients lost to follow-
up at an antiretroviral treatment clinic in johannesburg, South Africa.
Journal of acquired immune deficiency syndromes 2008, 47:101-107.
26. Brinkhof MW, Pujades-Rodriguez M, Egger M: Mortality of patients lost to
follow-up in antiretroviral treatment programmes in resource-limited
settings: systematic review and meta-analysis. PloS one 2009, 4:e5790.
27. Krebs DW, Chi BH, Mulenga Y, Morris M, Cantrell RA, Mulenga L, Levy J,
Sinkala M, Stringer JS: Community-based follow-up for late patients
enrolled in a district-wide programme for antiretroviral therapy in
Lusaka, Zambia. AIDS care 2008, 20:311-317.
28. Sutcliffe CG, Van Dijk JH, Bolton C, Cotham M, Tambatamba B, Moss WJ:
Differences in presentation, treatment initiation and response among
children infected with human immunodeficiency virus in urban and
rural Zambia. The Pediatric infectious disease journal 2010, 29.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2431/10/54/prepub
doi:10.1186/1471-2431-10-54
Cite this article as: Sutcliffe et al.: Secular trends in pediatric
antiretroviral treatment programs in rural and urban Zambia:
a retrospective cohort study. BMC Pediatrics 2010 10:54.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Sutcliffe et al. BMC Pediatrics 2010, 10:54
http://www.biomedcentral.com/1471-2431/10/54
Page 10 of 10